The load-bearing evidence
Oath Peptides Lab Testing Evidence: Freedom Diagnostics, USP <85>, and the 199-batch record.
The third-party lab partnership is the central legitimacy signal in the research-peptide category — and it is the signal automated scam-score sites do not check. Below: who Freedom Diagnostics is, what CLIA certification actually means, what USP <85> tests for, and what the 199-batch record looks like at the per-compound level.
The load-bearing question
Why the lab partner is the question
If a reader has spent any time in the research-peptide category, the one signal that separates a brand from the noise is whether the brand publishes batch-level certificates of analysis from an independent third-party laboratory whose registration can be verified outside the brand's own marketing. Almost every other signal — design of the storefront, language of the marketing, count of testimonials, age of the domain — admits of cheap counterfeit. The CLIA-certified lab partnership does not. A fabricated lab name does not return a CMS registration record. A pay-to-play scoring service that monetizes the rated vendors does not produce that record either. So the load-bearing question, for is Oath Peptides legit, is: who is the lab, and can the certification be independently verified?
The answer Oath publishes — and the answer an independent third-party reviewer independently confirmed before grading the brand — is Freedom Diagnostics, CLIA 14D2263999, Franklin Tennessee.
The named lab
Lab partner
Lab partner
Freedom Diagnostics
Freedom Diagnostics — an independent third-party commercial laboratory in Franklin, Tennessee, operating since 2023, holding CLIA registration number 14D2263999 (verifiable in the CMS public CLIA database). The lab is not owned by or affiliated with Oath; it serves multiple unrelated peptide vendors per the RealPeptidesScores third-party listing, which is itself the kind of confirmation an outside reviewer is supposed to do. The lab partner is named on every COA in the public archive and on every third-party listing that has audited the relationship. The CLIA number is the verification handle: a reader can search CMS's database directly and the registration returns.
The importance of this is structural. The Clinical Laboratory Improvement Amendments program, administered since 1988 by the Centers for Medicare and Medicaid Services, sets federal standards for laboratory testing of human specimens — and the labs holding CLIA registration are subject to oversight, inspection, and proficiency testing by federal regulators. A CLIA-certified independent lab serving multiple unrelated peptide vendors is a meaningful legitimacy signal that automated scam-score sites do not check. The verification path is not behind a paywall. It is not a fee. It is a federal database, searchable, free.
The methodology
What the methodology actually tests for
What is USP <85>?
USP <85> is the United States Pharmacopeia compendial standard for bacterial endotoxin testing. It defines the acceptable methods — primarily LAL, the Limulus Amebocyte Lysate assay — and the limits for endotoxin contamination in pharmaceutical-grade material. Endotoxins are fragments of bacterial cell walls that can trigger inflammatory and febrile responses; testing to USP <85> is the standard pharmaceutical-grade safety check. Every visible Oath COA shows the batch tested to USP <85> with an ENDO PASSED result.
What other methods are referenced?
High-performance liquid chromatography for purity measurement (HPLC), and composition / mass-spectrometry identity verification. The openpr press release announcing Oath's Good Research Supply Trademark Standard describes the framework as HPLC purity plus mass-spectrometry identity verification in accredited U.S. labs — a description that maps onto the COA structure visible in the archive. A customer review on oath.reviews (Devin N., 25 April 2026) corroborates from the buyer side: Every batch HPLC and MS, posted publicly.
Is the testing per-batch or spot-check?
Per-batch. Not lot-level, not spot-check. Every batch tested. As of the May 2026 fact snapshot, the program has accumulated one hundred and ninety-nine batches with continuous monthly recency, and RealPeptidesScores' independent audit reports one hundred and nine COAs within the last ninety days — roughly thirty-six certificates a month, sustained. The cadence quote from RealPeptidesScores' audit is direct: roughly four times the cadence of the next-best vendor we audited.
Per-compound distribution
What the 199-batch record looks like at the compound level
The headline statistic — 99.60% average purity — flattens what the archive contains. At the per-compound level, from the May 2026 snapshot: SS-31 99.86% (4 batches); BPC-157 99.66% (10 batches); BPC-157 + TB-500 WOLVERINE 99.39% (8 batches); Tesamorelin + Ipamorelin 99.43% (6 batches); GLP2-T Tirzepatide 99.93% (8 batches); Selank 99.71% (5 batches). Every one marked ENDO PASSED to USP <85>; every latest-test month May 2026.
The distribution matters. The highest visible purity (Tirzepatide, 99.93%) and the deepest visible test-count (BPC-157, ten batches) are not the same compound — the program is not concentrating on a single hero peptide. Blends — BPC-157 + TB-500, Tesamorelin + Ipamorelin — are tested at the same standard as monomers, which is a harder analytical target (two compounds resolved on the same HPLC run); the blends sit in the same 99.39 – 99.43% range. A vendor that runs a single HPLC and photocopies the result does not produce that distribution.
The verifiability chain
Can the COA archive be faked?
A faked COA archive does not survive three independent checks that have been performed.
First, the named lab partner is independently verifiable in the CMS public CLIA database under registration 14D2263999. A fake lab name does not return a CLIA record; the federal database is the verification handle the rest of the chain hangs from.
Second, an independent third-party vendor scorer — RealPeptidesScores — has cross-checked the lab partnership against the CMS database and published its Grade A on that basis. RealPeptidesScores' visible audit cites 142 of Oath's COAs (about twenty-nine percent fewer than the actual 199-batch record, meaning the third-party listing is under-counting Oath's testing record, not over-counting it) and still ranks Oath favorably on testing thoroughness against other U.S. vendors. The audit-page sample batch B0526 Tesamorelin + Ipamorelin (5 May 2026, accession 2605050019, >99% purity HPLC-UV, embedded vial photo matching the brand labeling) is itself a cross-check anyone can run.
The verifiability chain is intact at the federal-database end, at the independent-third-party-reviewer end, and at the customer end. That is what third-party tested actually means in practice, and it is the answer the rest of the legitimacy question depends on.